Tonix Pharmaceuticals Now Plans To Submit IND For Long Covid Treatment TNX-102 SL In Q4

Tonix Pharmaceuticals Holding Corp. (TNXP) on Tuesday said it received official minutes from the pre-IND meeting with FDA to develop TNX-102 SL as a potential treatment for Long COVID Syndrome.

Based on the minutes, the company plans to submit the investigational new drug application in the fourth quarter of 2021 for a Phase 2 study of TNX-102 SL in a subset of Long COVID patients whose symptoms overlap with fibromyalgia.

TNX-102 SL, a patented sublingual tablet formulation of cyclobenzaprine hydrochloride is in mid-Phase 3 development for the treatment of fibromyalgia.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT